Management of pregnancy in autoimmune rheumatic diseases: maternal disease course, gestational and neonatal outcomes and use of medications in the prospectiveItalian P-RHEUM.it study
Andreoli,L.,Gerardi,M. C.,Gerosa,M.,Rozza,D.,Crisafulli,F.,Erra,R.,Lini,D.,Trespidi,L.,Padovan,M.,Ruffilli,F.,Serale,F.,Cuomo,G.,Raffeiner,B.,Semeraro,P.,Tani,C.,Chimenti,M. S.,Conigliaro,P.,Hoxha,A.,Nalli,C.,Fredi,M.,Lazzaroni,M. G.,Filippini,M.,Taglietti,M.,Franceschini,F.,Zatti,S.,Loardi,C.,Orabona,R.,Ramazzotto,F.,Zanardini,C.,Fontana,G.,Gozzoli,G.,Barison,C.,Bizioli,P.,Caporali,R. F.,Carrea,G.,Ossola,M. W.,Maranini,B.,Silvagni,E.,Govoni,M.,Morano,D.,Verteramo,R.,Doria,A.,Del Ross,T.,Favaro,M.,Calligaro,A.,Tonello,M.,Larosa,M.,Zen,M.,Zambon,A.,Mosca,M.,Zucchi,D.,Elefante,E.,Gori,S.,Iannone,F.,Anelli,M. G.,Lavista,M.,Abbruzzese,A.,Fasano,C. G.,D'Angelo,S.,Cutro,M. S.,Picerno,V.,Carbone,T.,Padula,A. A.,Rovere-Querini,P.,Canti,V.,De Lorenzo,R.,Cavallo,L.,Ramoni,V.,Montecucco,C.,Codullo,V.,Milanesi,A.,Pazzola,G.,Comitini,G.,Marvisi,C.,Salvarani,C.,Epis,O. M.,Benedetti,S.,Di Raimondo,G.,Gagliardi,C.,Lomater,C.,Crepaldi,G.,Bellis,E.,Bellisai,F.,Garcia Gonzalez,E.,Pata,A. P.,Zerbinati,M.,Urban,M. L.,Mattioli,I.,Iuliano,A.,Sebastiani,G.,Brucato,A. L.,Bizzi,E.,Cutolo,M.,Santo,L.,Tonetta,S.,Landolfi,G.,Carrara,G.,Bortoluzzi,A.,Scire,C. A.,Tincani,A.,on behalf of the P-RHEUM.it Investigators of the Italian Society for Rheumatology (SIR)
DOI: https://doi.org/10.1136/rmdopen-2024-004091
2024-04-26
RMD Open
Abstract:Objectives To investigate pregnancy outcomes in women with autoimmune rheumatic diseases (ARD) in the Italian prospective cohort study P-RHEUM.it. Methods Pregnant women with different ARD were enrolled for up to 20 gestational weeks in 29 Rheumatology Centres for 5 years (2018–2023). Maternal and infant information were collected in a web-based database. Results We analysed 866 pregnancies in 851 patients (systemic lupus erythematosus was the most represented disease, 19.6%). Maternal disease flares were observed in 135 (15.6%) pregnancies. 53 (6.1%) pregnancies were induced by assisted reproduction techniques, 61 (7%) ended in miscarriage and 11 (1.3%) underwent elective termination. Obstetrical complications occurred in 261 (30.1%) pregnancies, including 2.3% pre-eclampsia. Two cases of congenital heart block were observed out of 157 pregnancies (1.3%) with anti-Ro/SSA. Regarding treatments, 244 (28.2%) pregnancies were treated with glucocorticoids, 388 (44.8%) with hydroxychloroquine, 85 (9.8%) with conventional synthetic disease-modifying anti-rheumatic drugs and 122 (14.1%) with biological disease-modifying anti-rheumatic drugs. Live births were 794 (91.7%), mostly at term (84.9%); four perinatal deaths (0.5%) occurred. Among 790 newborns, 31 (3.9%) were small-for-gestational-age and 169 (21.4%) had perinatal complications. Exclusive maternal breast feeding was received by 404 (46.7%) neonates. The Edinburgh Postnatal Depression Scale was compiled by 414 women (52.4%); 89 (21.5%) scored positive for emotional distress. Conclusions Multiple factors including preconception counselling and treat-to-target with pregnancy-compatible medications may have contributed to mitigate disease-related risk factors, yielding limited disease flares, good pregnancy outcomes and frequency of complications which were similar to the Italian general obstetric population. Disease-specific issues need to be further addressed to plan preventative measures.
rheumatology